(Updates with the latest stock move in the first paragraph and the headline.)
Candel Therapeutics (CADL) shares were down more than 30% in recent Friday trading, a day after the company said it priced a public offering of 10 million shares at $6 apiece and pre-funded warrants for about 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.
Underwriters have been granted a 30-day option to purchase up to an additional 2 million shares.
Net proceeds from the offering, which is expected to close around Dec. 16, will be used to continue the development of the company's product candidates and for general corporate purposes.
Price: 6.85, Change: -2.95, Percent Change: -30.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。